Document Detail


Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians.
MedLine Citation:
PMID:  24517108     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Renin-angiotensin-system (RAS) is an enzymatic cascade that plays a pivotal role in the development of arterial hypertension, kidney disease and cardiovascular disease. Inhibition of the RAS with angiotensin converting enzyme (ACE) inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) has proved to be a successful strategy for the treatment of hypertension and related cardiovascular disorders. However, by reducing feedback inhibition of renin release, the effects of ACE-Is and ARBs lead to an increase in plasma renin concentration (PRC) and activity (PRA), limiting a complete inhibition of the RAS. Consequently the effects of a different pharmacological strategy that completely blocks the RAS upstream has been assessed in the last years. In this context, aliskiren is the first representative of a new class of non-peptide orally active renin inhibitor that blocks the RAS at its rate-limiting step and induces a net reduction in PRA, angiotensin II and aldosterone levels. Aliskiren effectively reduces blood pressure as a monotherapy as well in combination therapy. In addition, aliskiren has a placebo-like tolerability profile at the licensed doses of 150 mg and 300 mg. Aliskiren also exhibits additive effects on blood pressure reduction when combined with drugs that lead to a reactive increase in the PRA, such as diuretics, ACE-Is or ARBs. In previous studies, aliskiren showed beneficial effects in patients with arterial hypertension and associated clinical conditions. However, later trials indicated that the use of aliskiren should be avoided in patients with renal failure or receiving ACE-Is or ARBs. The main aim of this review is to summarize the available data on its efficacy and safety profile, highlighting clinical implications from recent trials.
Authors:
Fabio Angeli; Gianpaolo Reboldi; Cristina Poltronieri; Enrica Angeli; Valentina De Filippo; Alessandra Crocetti; Claudia Bartolini; Cinzia D'Ambrosio; Paolo Verdecchia
Related Documents :
6681178 - Alcohol, personality and predisposition to essential hypertension.
24303178 - Benefits of omega-3 fatty acid against bone changes in salt-loaded rats: possible role ...
12452528 - Clinical phenotyping strategies in selection of tobacco smokers for future genotyping s...
17760788 - Blood hdl cholesterol levels influence association of alcohol intake with blood pressur...
11385568 - The post-spinel transformation in mg2sio4 and its relation to the 660-km seismic discon...
17281448 - Comparison of fmri bold effect and arterial pulsation harmonic distribution among diffe...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-2-10
Journal Detail:
Title:  Current drug safety     Volume:  -     ISSN:  2212-3911     ISO Abbreviation:  Curr Drug Saf     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2014-2-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270895     Medline TA:  Curr Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HIV, HBV, HCV and T. pallidum infections among blood donors and Transfusion-related complications am...
Next Document:  Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative...